InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.071 -0.069 (-49.29%)+
Announcement
Release
11 Nov 2025 9:26AM
Price at Release
$0.140
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Ltd (NSB), an Australian biotechnology company, has announced that the fourth patient has commenced treatment under their Special Access Program using the StemSmart™ MSC therapy. This program targets patients with fistulising Crohn’s disease who have exhausted conventional treatment options. The real-world data from this program will inform the design of a planned Phase 2 clinical trial set to begin in CY2026. This initiative aligns with NSB’s broader strategy to make the treatment available to patients with refractory and fistulising Crohn’s disease. The company also highlights the potential of StemSmart™ in other therapeutic areas, such as organ transplant immune tolerance and lung inflammatory diseases.
Key Points
  • Fourth patient has commenced treatment under NSB's Special Access Program.
  • The treatment involves NSB's patented StemSmartâ„¢ MSC product for patients with fistulising Crohn’s disease.
  • This treatment aims to support a Phase 2 clinical trial planned for CY2026.
  • The Special Access Scheme Category B allows treatment for patients with no effective conventional therapy alternatives.
  • Initial patient treatment results are expected in January 2026.
  • StemSmartâ„¢ therapy is positioned for additional commercial opportunities beyond Crohn’s disease.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.